Video Interview: Rigontec CEO Details Immuno-Oncology Strategy
This article was originally published in Scrip
Executive Summary
Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I, one of the essential pathways of the innate immune system. Rigontec's proprietary agonists are designed to activate RIG-I specifically, inducing both immediate and long-term anti-tumor immunity, and achieving substantial local and systemic tumor regression in several relevant in vivo models.